Medcaptain Medical Technology Co., Ltd. (HKG:2041)
Hong Kong · Delayed Price · Currency is HKD 8.78
-0.24 (-2.61%)
Sep 11, 2026, 4:08 PM HKT
HKG:2041 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| 1,687 | 1,619 | 1,399 | 1,313 | |
Revenue Growth | - | 15.71% | 6.55% | - |
Cost of Revenue | 769.66 | 749.49 | 704.29 | 661.86 |
Gross Profit | 917.07 | 869.66 | 695.07 | 651.44 |
Selling, General & Admin | 568.21 | 527.13 | 498.8 | 463.35 |
Research & Development | 280.68 | 274.19 | 290.51 | 281.1 |
Other Operating Expenses | -17.99 | -19.18 | -33.06 | -51.79 |
Operating Expenses | 832.44 | 783.68 | 758.01 | 692.75 |
Operating Income | 84.63 | 85.98 | -62.94 | -41.32 |
Interest Expense | -18.42 | -18.33 | -16 | -21.42 |
Interest & Investment Income | 9.76 | 9.24 | 7.29 | 4.91 |
Earnings From Equity Investments | - | - | -0.9 | -1.27 |
Currency Exchange Gain (Loss) | -3.62 | 2.1 | 1.73 | 10.92 |
EBT Excluding Unusual Items | 72.36 | 78.99 | -70.82 | -48.18 |
Gain (Loss) on Sale of Investments | -0.38 | 0.22 | 1.38 | 1.11 |
Gain (Loss) on Sale of Assets | -0.69 | -0.97 | 0.2 | 0.27 |
Other Unusual Items | 0.48 | 0.48 | -1.27 | -3.02 |
Pretax Income | 71.77 | 78.72 | -70.5 | -49.82 |
Income Tax Expense | 28.78 | 27.98 | 26.12 | 14.68 |
Earnings From Continuing Operations | 42.99 | 50.74 | -96.62 | -64.51 |
Minority Interest in Earnings | -2.23 | -1.85 | 0.22 | 0.8 |
Net Income | 40.76 | 48.89 | -96.4 | -63.71 |
Net Income to Common | 40.76 | 48.89 | -96.4 | -63.71 |
Net Income Growth | - | - | - | - |
Shares Outstanding (Basic) | 500 | 500 | - | - |
Shares Outstanding (Diluted) | 500 | 500 | - | - |
Shares Change | - | - | - | - |
EPS (Basic) | 0.08 | 0.10 | - | - |
EPS (Diluted) | 0.08 | 0.10 | - | - |
EPS Growth | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Free Cash Flow | 179.69 | 113.06 | 63.21 | -14.8 |
Free Cash Flow Per Share | 0.36 | 0.23 | - | - |
Gross Margin | 54.37% | 53.71% | 49.67% | 49.60% |
Operating Margin | 5.02% | 5.31% | -4.50% | -3.15% |
Profit Margin | 2.42% | 3.02% | -6.89% | -4.85% |
Free Cash Flow Margin | 10.65% | 6.98% | 4.52% | -1.13% |
EBITDA | 171.21 | 172.05 | 23.25 | 41.57 |
EBITDA Margin | 10.15% | 10.63% | 1.66% | 3.16% |
D&A For EBITDA | 86.58 | 86.07 | 86.19 | 82.89 |
EBIT | 84.63 | 85.98 | -62.94 | -41.32 |
EBIT Margin | 5.02% | 5.31% | -4.50% | -3.15% |
Effective Tax Rate | 40.10% | 35.54% | - | - |